Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells
- PMID: 19458000
- PMCID: PMC2708622
- DOI: 10.1128/JVI.00182-09
Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells
Abstract
Primary HIV-1 infection (PHI) is marked by a flu-like syndrome and high levels of viremia that decrease to a viral set point with the first emergence of virus-specific CD8+ T-cell responses. Here, we investigated in a large cohort of 527 subjects the immunodominance pattern of the first virus-specific cytotoxic T-lymphocyte (CTL) responses developed during PHI in comparison to CTL responses in chronic infection and demonstrated a distinct relationship between the early virus-specific CTL responses and the viral set point, as well as the slope of CD4+ T-cell decline. CTL responses during PHI followed clear hierarchical immunodominance patterns that were lost during the transition to chronic infection. Importantly, the immunodominance patterns of human immunodeficiency virus type 1 (HIV-1)-specific CTL responses detected in primary, but not in chronic, HIV-1 infection were significantly associated with the subsequent set point of viral replication. Moreover, the preservation of the initial CD8+ T-cell immunodominance patterns from the acute into the chronic phase of infection was significantly associated with slower CD4+ T-cell decline. Taken together, these data show that the specificity of the initial CTL response to HIV is critical for the subsequent control of viremia and have important implications for the rational selection of antigens for future HIV-1 vaccines.
Figures
Similar articles
-
Human immunodeficiency virus type 1 replication, immune activation, and circulating cytotoxic T cells against uninfected CD4+ T cells.J Clin Immunol. 2000 May;20(3):175-86. doi: 10.1023/a:1006633429087. J Clin Immunol. 2000. PMID: 10941825
-
CD8(+)-Cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription.J Virol. 2000 May;74(10):4456-64. doi: 10.1128/jvi.74.10.4456-4464.2000. J Virol. 2000. PMID: 10775581 Free PMC article.
-
Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection.J Virol. 2002 Sep;76(17):8690-701. doi: 10.1128/jvi.76.17.8690-8701.2002. J Virol. 2002. PMID: 12163589 Free PMC article.
-
Virus-specific cytotoxic T lymphocyte responses in patients infected with the human immunodeficiency virus, HIV-1.Cell Mol Biol (Noisy-le-grand). 1994;40 Suppl 1:45-8. Cell Mol Biol (Noisy-le-grand). 1994. PMID: 7950861 Review.
-
Immunodominance of HIV-1-specific CD8(+) T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics.Trends Immunol. 2005 Mar;26(3):166-71. doi: 10.1016/j.it.2005.01.003. Trends Immunol. 2005. PMID: 15745859 Review.
Cited by
-
Short-course antiretroviral therapy in primary HIV infection.N Engl J Med. 2013 Jan 17;368(3):207-17. doi: 10.1056/NEJMoa1110039. N Engl J Med. 2013. PMID: 23323897 Free PMC article. Clinical Trial.
-
Immune screening identifies novel T cell targets encoded by antisense reading frames of HIV-1.J Virol. 2015 Apr;89(7):4015-9. doi: 10.1128/JVI.03435-14. Epub 2015 Jan 14. J Virol. 2015. PMID: 25589651 Free PMC article.
-
Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.J Virol. 2019 Sep 30;93(20):e00814-19. doi: 10.1128/JVI.00814-19. Print 2019 Oct 15. J Virol. 2019. PMID: 31375576 Free PMC article.
-
Reduced eIF3d accelerates HIV disease progression by attenuating CD8+ T cell function.J Transl Med. 2019 May 22;17(1):167. doi: 10.1186/s12967-019-1925-0. J Transl Med. 2019. PMID: 31118081 Free PMC article.
-
Very early antiretroviral therapy permits CD8 T cells to keep HIV reservoirs at bay.Ann Transl Med. 2017 Nov;5(21):434. doi: 10.21037/atm.2017.08.38. Ann Transl Med. 2017. PMID: 29201886 Free PMC article. No abstract available.
References
-
- Addo, M. M., X. G. Yu, A. Rathod, D. Cohen, R. L. Eldridge, D. Strick, M. N. Johnston, C. Corcoran, A. G. Wurcel, C. A. Fitzpatrick, M. E. Feeney, W. R. Rodriguez, N. Basgoz, R. Draenert, D. R. Stone, C. Brander, P. J. Goulder, E. S. Rosenberg, M. Altfeld, and B. D. Walker. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 772081-2092. - PMC - PubMed
-
- Altfeld, M., E. T. Kalife, Y. Qi, H. Streeck, M. Lichterfeld, M. N. Johnston, N. Burgett, M. E. Swartz, A. Yang, G. Alter, X. G. Yu, A. Meier, J. K. Rockstroh, T. M. Allen, H. Jessen, E. S. Rosenberg, M. Carrington, and B. D. Walker. 2006. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8+ T cell response against HIV-1. PLoS Med. 3e403. - PMC - PubMed
-
- Bashirova, A. A., G. Bleiber, Y. Qi, H. Hutcheson, T. Yamashita, R. C. Johnson, J. Cheng, G. Alter, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, M. May, F. Maldarelli, L. Jacobson, J. O'Brien, S. A. Telenti, and M. Carrington. 2006. Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J. Virol. 806757-6763. - PMC - PubMed
-
- Betts, M. R., D. R. Ambrozak, D. C. Douek, S. Bonhoeffer, J. M. Brenchley, J. P. Casazza, R. A. Koup, and L. J. Picker. 2001. Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 7511983-11991. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
- HHMI/Howard Hughes Medical Institute/United States
- P01 AI074415/AI/NIAID NIH HHS/United States
- U01 AI043638/AI/NIAID NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- AI43638/AI/NIAID NIH HHS/United States
- R24 AI106039/AI/NIAID NIH HHS/United States
- R01 AI50429/AI/NIAID NIH HHS/United States
- HHSN261200800001C/CA/NCI NIH HHS/United States
- R01 AI050429/AI/NIAID NIH HHS/United States
- N01CO12400/CA/NCI NIH HHS/United States
- U01 AI052403/AI/NIAID NIH HHS/United States
- N01-CO-12400/CO/NCI NIH HHS/United States
- HHSN261200800001E/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
